GT Biopharma (NASDAQ:GTBP) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of GT Biopharma (NASDAQ:GTBP) to a strong sell rating in a report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GT Biopharma in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, GT Biopharma has an average rating of “Sell”.

GT Biopharma Price Performance

GTBP stock opened at $11.63 on Friday. GT Biopharma has a 1-year low of $4.91 and a 1-year high of $34.25. The business has a 50-day moving average price of $8.01 and a 200 day moving average price of $9.66. The company has a market capitalization of $20.93 million, a P/E ratio of -0.08 and a beta of 0.91.

GT Biopharma (NASDAQ:GTBP) last issued its earnings results on Friday, August 14th. The company reported ($3.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.00) by ($1.00). On average, analysts anticipate that GT Biopharma will post -10.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GT Biopharma

A hedge fund recently bought a new stake in GT Biopharma stock. 49 Wealth Management LLC bought a new position in GT Biopharma, Inc. (NASDAQ:GTBP) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 64,000 shares of the company’s stock, valued at approximately $31,000. 49 Wealth Management LLC owned approximately 0.14% of GT Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 8.15% of the company’s stock.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).